Investor Relations

Stock Quote (NASDAQ: DNDN)
Price:
0.13
Change:
- 0.02
Volume:
22,715,200
4:00 PM ET on Nov 18, 2014
Delayed at least 20 minutes.
Provided by eSignal.
Stock price graph
     

Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.

Dendreon has reached agreements with certain of its senior noteholders on the terms of a financial restructuring. Operations will continue in the ordinary course and PROVENGE will remain available. Additional information about the financial restructuring is available here: https://cases.primeclerk.com/dendreon.

View all »   RSSRecent Releases

Nov 10, 2014
Dendreon Reaches Agreements on Terms of Financial Restructuring

Jul 30, 2014
Dendreon Names W. Thomas Amick President and Chief Executive Officer

Jun 9, 2014
Dendreon Announces Leadership Transition



View all »Webcasts

May 8, 2014 at 9:00 AM ET
Q1 2014 Earnings Conference Call

Mar 4, 2014 at 11:20 AM ET
Cowen and Company 34th Annual Health Care Conference



View all »Presentations

MEDCAC 11.17.10 Presentation PDF 397.5 KB
Updated Results of the IMPACT Trial of Sipuleucel-T for Metastatic, Castration-Resistant Prostate Cancer (CRPC) PDF 421.1 KB

Contact

Investor Relations
206-455-2220
ir@dendreon.com

Media
206-829-1622
media@dendreon.com